These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 27671969

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
    Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S.
    J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review.
    Boskey ER, Taghinia AH, Ganor O.
    JAMA Surg; 2019 Feb 01; 154(2):159-169. PubMed ID: 30516808
    [Abstract] [Full Text] [Related]

  • 5. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
    Fung R, Hellstern-Layefsky M, Tastenhoye C, Lega I, Steele L.
    J Sex Med; 2016 Nov 01; 13(11):1765-1772. PubMed ID: 27693265
    [Abstract] [Full Text] [Related]

  • 6. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
    Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J.
    J Clin Endocrinol Metab; 2003 Dec 01; 88(12):5723-9. PubMed ID: 14671159
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
    Dinger J, Bardenheuer K, Heinemann K.
    Climacteric; 2016 Aug 01; 19(4):349-56. PubMed ID: 27174159
    [Abstract] [Full Text] [Related]

  • 14. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher AD, Toye K, Kaufman JM, T'Sjoen G.
    J Sex Med; 2014 Aug 01; 11(8):1999-2011. PubMed ID: 24828032
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
    Cunha FS, Domenice S, Sircili MHP, Mendonca BB, Costa EMF.
    Clinics (Sao Paulo); 2018 Aug 01; 73():e86. PubMed ID: 29723345
    [Abstract] [Full Text] [Related]

  • 17. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment.
    Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Peerdeman SM, Kreukels BPC, den Heijer M.
    Brain; 2018 Jul 01; 141(7):2047-2054. PubMed ID: 29688280
    [Abstract] [Full Text] [Related]

  • 18. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
    Salakphet T, Mattawanon N, Manojai N, Muangmool T, Tangpricha V.
    J Sex Med; 2022 May 01; 19(5):864-871. PubMed ID: 35379590
    [Abstract] [Full Text] [Related]

  • 19. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.
    Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Silverberg MJ, Safer J, Slovis J, Tangpricha V, Goodman M.
    Ann Intern Med; 2018 Aug 21; 169(4):205-213. PubMed ID: 29987313
    [Abstract] [Full Text] [Related]

  • 20. Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy.
    Dix C, Moloney M, Tran HA, McFadyen JD.
    Thromb Haemost; 2024 May 21; 124(5):387-398. PubMed ID: 37816389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.